BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 16832587)

  • 1. Pituitary apoplexy after leuprolide.
    Davis A; Goel S; Picolos M; Wang M; Lavis V
    Pituitary; 2006; 9(3):263-5. PubMed ID: 16832587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pituitary apoplexy following gonadotropin-releasing hormone agonist administration with gonadotropin-secreting pituitary adenoma.
    Sasagawa Y; Tachibana O; Nakagawa A; Koya D; Iizuka H
    J Clin Neurosci; 2015 Mar; 22(3):601-3. PubMed ID: 25455737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pituitary apoplexy after leuprolide administration for carcinoma of the prostate.
    Morsi A; Jamal S; Silverberg JD
    Clin Endocrinol (Oxf); 1996 Jan; 44(1):121-4. PubMed ID: 8706284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pituitary apoplexy induced by Gonadotropin-releasing hormone agonists for treating prostate cancer-report of first Asian case.
    Huang TY; Lin JP; Lieu AS; Chen YT; Chen HS; Jang MY; Shen JT; Wu WJ; Huang SP; Juan YS
    World J Surg Oncol; 2013 Oct; 11():254. PubMed ID: 24088191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pituitary apoplexy induced by gonadotropin-releasing hormone (GnRH) agonist administration for treatment of prostate cancer: a systematic review.
    Raj R; Elshimy G; Jacob A; Arya PVA; Unnikrishnan DC; Correa R; Myint ZW
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2337-2347. PubMed ID: 34156518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Two cases of non-functional gonadotroph adenoma pituitary apoplexy following GnRH-agonist treatment revealing gonadotroph adenoma and pseudopituitary apoplexy after GnRH administration].
    Hernandez Morin N; Huet D; Hautecouverture M
    Ann Endocrinol (Paris); 2003 Jun; 64(3):227-31. PubMed ID: 12910066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pituitary apoplexy of a gonadotroph adenoma following gonadotrophin releasing hormone agonist therapy for prostatic cancer.
    Reznik Y; Chapon F; Lahlou N; Deboucher N; Mahoudeau J
    J Endocrinol Invest; 1997 Oct; 20(9):566-8. PubMed ID: 9413812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pituitary Apoplexy After Initial Leuprolide Injection.
    Fabiano AJ; George S
    World Neurosurg; 2016 Nov; 95():616.e7-616.e9. PubMed ID: 27586180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pituitary apoplexy: a rare complication of leuprolide therapy in prostate cancer treatment.
    Tanios G; Mungo NA; Kapila A; Bajaj K
    BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28710301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer.
    Guerra Y; Lacuesta E; Marquez F; Raksin PB; Utset M; Fogelfeld L
    Pituitary; 2010; 13(1):54-9. PubMed ID: 19842040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pituitary apoplexy induced by triptorelin in patient with prostate cancer.
    Guerrero-Pérez F; Marengo AP; Planas-Vilaseca A; Flores-Escobar V; Villabona-Artero C
    Endocrinol Nutr; 2015 Oct; 62(8):411-2. PubMed ID: 26184059
    [No Abstract]   [Full Text] [Related]  

  • 12. A Case of Pituitary Apoplexy Following Leuprolide Injection for Prostate Cancer.
    Kim KW; Chee S; Sunkara N; Baker MH
    R I Med J (2013); 2024 Feb; 107(2):7-9. PubMed ID: 38285742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
    Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
    Int J Urol; 2006 Jan; 13(1):87-8. PubMed ID: 16448441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late onset of pituitary apoplexy following gonadotropin-releasing hormone agonist for prostate cancer treatment.
    Elshimy G; Raj R; Jacob A; Correa R
    BMJ Case Rep; 2022 Mar; 15(3):. PubMed ID: 35256375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
    Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
    Int J Urol; 2006 Mar; 13(3):303-4. PubMed ID: 16643633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pituitary apoplexy after leuprolide administration for carcinoma of the prostate: what's new?
    Faustini-Fustini M
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):378. PubMed ID: 9156052
    [No Abstract]   [Full Text] [Related]  

  • 17. Delayed pituitary apoplexy in patient with advanced prostate cancer treated with gonadotrophin-releasing hormone agonists.
    Sinnadurai M; Cherukuri RK; Moses RG; Nasser E
    J Clin Neurosci; 2010 Sep; 17(9):1201-3. PubMed ID: 20605467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary apoplexy and sudden blindness following the administration of gonadotrophin releasing hormone.
    Masson EA; Atkin SL; Diver M; White MC
    Clin Endocrinol (Oxf); 1993 Jan; 38(1):109-10. PubMed ID: 8435878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gonadotropin-releasing hormone agonist-induced pituitary apoplexy in treatment of prostate cancer: case report and review of literature.
    Hands KE; Alvarez A; Bruder JM
    Endocr Pract; 2007 Oct; 13(6):642-6. PubMed ID: 17954421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pituitary apoplexy probably due to TRH and GnRH stimulation tests in a patient with acromegaly.
    Dökmetaş HS; Selçuklu A; Colak R; Unlühizarci K; Bayram F; Keleştimur F
    J Endocrinol Invest; 1999 Oct; 22(9):698-700. PubMed ID: 10595834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.